Data from this trial showed that all the four stage III patients remained cancer-free with no disease recurrence, while the two metastatic patients who did relapse were found to be very responsive to anti-programmed cell death protein 1 (anti-PD-1) therapy. The gene discussed is PDCD1; the disease is cancer.